Evidence map›Paper›PMID 17989704›Full record

ArticleGene therapy2008

In vitro and in vivo analysis of expression cassettes designed for vascular gene transfer.

S J White, E D Papadakis, C A Rogers, J L Johnson, E A L Biessen, A C Newby

Open access · greenAbstract readComparative Study
In one paragraph

Article in Gene therapy, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.4field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 14 citations in OpenAlex.

  1. Short regulatory DNA sequences to target brain endothelial cells for gene therapy.Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism · 2022
    Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 4 institutions in 2 countries.

S J WhiteBristol Heart Institute, University of Bristol, Bristol, UK. steve.white@bris.ac.uk
E D Papadakis
C A Rogers
J L Johnson
E A L Biessen
A C Newby
NIHR Bristol Cardiovascular Biomedical Research Unit · GBLeiden University · NLNIHR Evaluation Trials and Studies Coordinating Centre · GBUniversity of Bristol · GB

Funding

British Heart Foundation FS/03/096/16318
6 · The paper itself

Abstract

Increasing the level and duration of transgene expression and restricting expression to vascular cells are important goals for clinically useful gene therapy vectors. We evaluated several promoters, enhancers and introns in endothelial, smooth muscle and liver cells in tissue culture and in vivo, comparing local delivery to the carotid artery with intravenous delivery to the liver. A 1800-bp fragment of the oxidized LDL receptor (LOX-1) promoter showed highest in vivo activity in the carotid artery, achieving 39% the activity of the reference cytomegalovirus promoter, with 188-fold greater specificity for carotid artery over liver. An enhancer from the Tie2 gene in combination with the intracellular adhesion molecule-2 promoter improved endothelial specificity of plasmid vectors, increased the expression from adenoviral vectors in cultured endothelial cells and doubled the specificity for carotid artery over liver in vivo. Adding a short intron to expression cassettes increased expression in both endothelial and smooth muscle cells in vitro; however, the eNOS enhancer failed to consistently increase the expression or endothelial specificity of the vector. In conclusion, elements from the LOX-1 promoter and Tie2 enhancer together with an intron can be used to improve vectors for vascular gene transfer.

Indexed as

AdenoviridaeChi-Square DistributionEndothelial CellsEnhancer Elements, GeneticGene ExpressionGenetic EngineeringGenetic TherapyGenetic VectorsHumansIntronsLinear ModelsLiverLuciferasesMuscle, Smooth, VascularPromoter Regions, GeneticReceptor, TIE-2LuciferasesOLR1 protein, humanReceptor, TIE-2Scavenger Receptors, Class E

Identifiers

PMID17989704
PMCPMC2850989
OpenAlexW2067051683

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.